AstraZeneca delivers 12 positive Phase III programme readouts as stock rises 2.3%

Traders Union
All News
Business & Wealth
Companies
AstraZeneca stock rises 2.3% today

Highlights

AstraZeneca reported 12 positive Phase III programme readouts year-to-date and 47 major-market regulatory approvals since Q4 2025.
On October 26, 2026, three cancer medicines delivered statistically significant survival benefits in Phase III trials, including Sonesitatug vedotin for advanced gastric cancer.
77 of 94 analysts rate AstraZeneca stock a buy, with a median price target of $16,020 about 22.6% above current levels.

AstraZeneca announced it delivered 12 key positive Phase III programme readouts this year. Since its Q4 2025 results, the company secured 47 approvals in major markets. On October 26, 2026, AstraZeneca reported positive Phase III data for three cancer medicines, including statistically significant survival benefits for Sonesitatug vedotin in advanced gastric and gastroesophageal junction cancer, according to Yahoo! Finance.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish structure forms as shares hit new weekly high after data release

Price moved through the prior weekly high at GBX12,976, setting a new high for the week. AstraZeneca shares are supported by an emerging bullish structure, trading above both the MA-20 and MA-50, though still below the MA-200. Stoch RSI is nearing overbought territory, suggesting the recent advance is beginning to look stretched.

Odds favor further gains as traders eye confirmation above recent peak

To gauge whether recent developments are being priced in, traders should watch how AstraZeneca shares behave relative to GBX13,429 for confirmation and GBX12,976 for a reversal. The stock recently pushed above the weekly high at GBX12,976 and set a fresh weekly peak. Even so, from here, the probability of further upside over the next five trading days stands at more than 80%, with downside probability less than 20%, and the expected trading range is GBX12,914 to GBX13,213. A close above GBX13,429 would indicate strong buyer follow-through, while a drop back below GBX12,976 would signal that the move is being rejected. On the weekly chart, the longer-term picture stays constructive.

Earlier, analysts noted that AstraZeneca shares were consolidating in a narrow range, with technicals signaling a potential breakout. The string of positive late-stage trial results and regulatory approvals this year now strengthens the bullish outlook, with GBX13,429 marking a critical level for confirmation of further upside momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.